Skip to Content

Vanderbilt-Ingram Cancer CenterVanderbilt-Ingram Cancer Center

 

VICC toll-free number 1-877-936-8422

Publications

Laboratory Publications

  1. Shi H*, Moriceau G*, Kong X, Koya RC, Nazarian R, Pupo G, Bacchiocchi A, Dahlman KB, Chmielowski B, Sosman JA, Halaban R, Kefford RF, Long GV, Ribas A, Lo RS (2012). MEK1 exon 3 mutations in V600E/KBRAF melanomas do not confer resistance to B-RAF inhibitors. Cancer Discovery. (in press) *These authors contributed equally.
  2. Lovly C*, Dahlman KB*, Fohn L*, Su Z*, Dias-Santagata D, Hicks DJ, Hucks D, Berry, E, Terry C, Duke M Su Y, Sobolik-Delmaire T, Richmond A, Kelley MC, Vnencak-Jones CL, Iafrate JA, Sosman J, Pao W (2012). Routine multiples mutational profiling of melanomas enables enrollment in genotype-driven therapeutic trials. PLoS ONE (in press) *These authors contributed equally.
  3. Su Y, Kelley MC, Splittgerber RC, Kantrow S, Short S, Sobolik-Delmaire T, Dahlman KB, Jiang A, Shyr Y, Levy S, Sosman J, Richmond A (2011). RAF265 inhibits the growth of advanced human melanoma independent of BRAF mutation status. Clinical Cancer Research. (in press)
  4. Shi H, Moriceau G, Kong X, Lee M, Ribas A, Koya R, Ng C, Chodon T, Nelson S, Lee H, Long G, Scolyer R, Kefford R, Sosman J, Dahlman KB, Lo R (2012) Melanoma whole exome sequencing identifies V600EB-RAF amplification-mediated acquired B-RAF inhibitor resistance. Nature Communications 3:724.
  5. Poulikakos, PI, Persaud Y, Janakiraman M, Kong X, Ng C, Moriceau G, Shi H, Atefi M, Titz B, Gabay MT, Salton M, Dahlman KB, Madhavi T, Wargo JA, Flaherty KT, Kelley MC, Misteli T, Chapman PB, Sosman JA, Graeber TG, Ribas A, Lo RS, Rosen N, Solit D (2011). RAF inhibitor resistance is mediated by dimerization of aberrantly spliced BRAF(V600E). Nature. 480: 387-390.
  6. Villanueva J, Vultur A, Lee JT, Somasundaram R, Fukunaga-Kalabis M, Cipolla AK, Wubbenhorst B, Xu X, Gimotty PA, Kee D, Santiago-Walker AE, Letrero R, D'Andrea K, Pushparajan A, Hayden JE, Dahlman KB, Laquerre S, McArthur GA, Sosman JA, Nathanson KL, Herlyn M (2010). Acquired resistance to BRAF inhibitors mediated by a RAF kinase switch in melanoma can be overcome by cotargeting MEK and IGF-1R/PI3K. Cancer Cell. 18: 683-695.

Abstracts

  1. Dahlman KB*, Xia J*, Hutchinson K, Ng C, Hucks D, Jia P, Atefi M, Su Z, Branch S, Lyle PL, Hicks D, Bozon V, Glaspy JA, Netterville JL, Venencak-Jones C, Sosman J, Ribas A, Zhao Z, Pao W (2012). BRAF L597 mutations in melanoma are associated with sensitivity to MEK inhibitors. *These authors contributed equally. 2012 AACR Annual Meeting, Chicago, IL (Poster)
  2. Dahlman KB, Xia J, Hucks D, Hutchinson K, Su Z, Jia P, Hicks D, Venencak-Jones C, Sosman J, Zhao Z, Pao W (2011). Uncovering drivers of melanoma tumorigenesis by whole-genome sequencing. Illumina Nashville Users Group Meeting, Nashville, TN (Invited speaker)
  3. Su Y, Kelley MC, Splittgerber RC, Kantrow S, Short SP, Sobolik-Delmaire T, Zaja-Milatovic S, Liu Y, Vilgelm AE, Hawkins OE, Dahlman KB, Jiang A, Lu P, Shyr Y, Stuart DD, Levy S, Sosman JA, Richmond A (2011). RAF265 Inhibits the Growth of Advanced Human Melanoma Tumors. 2011 International Melanoma Congress, Tampa, FL (Poster)
  4. Hatakeyama H, Cheng H, Fertig E, Dahlman KB, Su Z, Slebos R, Pao W, Chung CH (2011). Epithelial-to-mesenchymal transition and cetuximab resistance in head and neck squamous cell carcinoma. NCI Translational Research meeting, Washington DC.
  5. Vnencak-Jones CL, Su Z, Fohn L, Dahlman KB, Levy M, Sosman J, Pao W (2011). Tumor molecular profiling of non-squamous non-small cell lung cancer and melanoma in a clinical laboratory to optimize clinical management decisions. American College of Medical Genetics, Vancouver, BC Canada (Poster)
  6. Hatakeyama H, Dahlman KB, Su Z, Slebos R, Pao W, Chung CH (2011) Nuclear factor-kappa B activation and cetuximab-resistance in HNSCC cell lines. American Association for Cancer Research 101st Annual Meeting, Orlando, FL (Poster).